New Guidance on Investigational Medicinal Products (IMPs) and Non Investigational Medicinal products (NIMPs)
The EU Commission has published a revision of the Guidance on Investigational Medicinal Products (IMPs) and Non investigational Medicinal Products (NIMPs), which had been published in 2007, completing the detailed guidance CT-1. The main change relates to point 3.3 and the additional annex 2 setting out documentation requirements for NIMPs in the application dossier.
In 3.3., it is pointed out that documentation requirements in the application dossier for IMPs also apply to NIMPs. However, depending on the knowledge of the NIMP, documentation can be reduced to a so called 'simplified dossier' described in detail in Annex 2 of the document. To determine the required data, a risk-based approach needs to be applied.
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
22.01.2025Final ICH E6(R3) Guideline on GCP released
14.01.2025Swissmedic Position Paper on Clinical Trials
14.01.2025Annual Report of the GCP Inspectors' Working Group
05.12.2024ICH E6(R3) Annex 2 Draft Guideline Released
05.12.2024ICH M15 Draft Guideline on Model-Informed Drug Development
07.11.2024Interim-Report on EMA's Clinical Study Data Proof-of-Concept Pilot